Skip to content
Parakho

Bharat Parenterals Ltd

NSE BPLPHARMABSE 541096bplindia.in

Q1 FY27, unaudited

Revenue
₹93.74 Cr
Profit after tax
₹-3.56 Cr

As filed with the exchange, consolidated basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with BSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, consolidated basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations93.74−19.19%345.43
Other income1.11+4.85%9.54
Total income94.85−18.97%354.98
Employee benefit expense18.84+23.13%67.28
Finance costs2.45−33.54%12.53
Depreciation & amortisation8.69+1.01%34.25
Total expenses96.34−15.87%376.40
Profit before tax-1.49−158.78%-21.42
Tax expense2.07−39.29%5.88
Profit after tax-3.56−309.57%-27.31
Total comprehensive income-3.46−279.77%-26.73
Earnings per share
Earnings per share, basic₹-5.17₹-39.62
Earnings per share, diluted₹-5.17₹-39.62

Q1 FY27 — unaudited, from the company’s filing with BSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with BSE. Source

FY26 — from the company’s filing with BSE. Source

Q1 FY27 results for every company Parakho holds

Earnings call

Q4 FY26

Bharat Parenterals reported consolidated FY26 revenue of INR345.4 crores, roughly flat year-on-year, with consolidated EBITDA rising to INR15.8 crores from INR2.7 crores, driven mainly by a narrowing of losses at subsidiary Innoxel Lifesciences. Standalone BPL revenue declined about 23% due to deferred export tenders, exit from low-margin business, and production line upgrades, while Varenyam Healthcare turned profitable with 13.7% revenue growth and Innoxel grew revenue 174.1% on licensing and milestone income. Management issued FY27 guidance across its three operating businesses and described FY26 as a transition year ahead of an expected commercial inflection.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote.

Read the full summary

Filings

12 shown · 53 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Industry

Healthcare › Pharmaceuticals

Classification as published by BSE.

Companies also in Pharmaceuticals, in alphabetical order

All 196 companies in Pharmaceuticals

Page generated from filings held to 08 Oct 2026.